Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Canakinumab + Spartalizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Canakinumab||Ilaris||ACZ-885||Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077).|
|Spartalizumab||PDR001|PDR-001||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04028245||Phase I||Canakinumab + Spartalizumab||A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)||Recruiting|
|NCT02900664||Phase I||Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab||A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)||Active, not recruiting|
|NCT03484923||Phase II||LAG525 + Spartalizumab Capmatinib + Spartalizumab Canakinumab + Spartalizumab||Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)||Recruiting|